Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Schizophrenia

  Free Subscription


22.06.2026

1 Biol Psychiatry
1 Br J Psychiatry
1 J Clin Psychopharmacol
1 J Int Neuropsychol Soc
6 Mol Psychiatry
2 Nat Ment Health
1 Neuropsychopharmacology
2 Psychiatry Res
2 Psychol Med
10 Schizophr Res


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Biol Psychiatry

  1. VOLPI T, Radhakrishnan R, Hird R, Naganawa M, et al
    Lower Muscarinic M1 Receptor Availability in Schizophrenia: In Vivo PET Evidence.
    Biol Psychiatry. 2026 Jun 12:S0006-3223(26)01316.
    PubMed         Abstract available


    Br J Psychiatry

  2. BAUM ML, Blackman G, Al-Diwani A, Handel A, et al
    Ethical issues in the clinical use of diagnostic technologies for rare causes of psychosis.
    Br J Psychiatry. 2026 Jun 16:1-6. doi: 10.1192/bjp.2026.10675.
    PubMed         Abstract available


    J Clin Psychopharmacol

  3. ZHAND N, Joober R, Labelle A, Iftikhar F, et al
    Safety of Adjunct Low-Dose Methylphenidate Extended-Release for Cognitive Deficits in Stable Schizophrenia: Results From an Open-Label, Randomized Crossover Trial.
    J Clin Psychopharmacol. 2026 Jun 18. doi: 10.1097/JCP.0000000000002220.
    PubMed         Abstract available


    J Int Neuropsychol Soc

  4. FISZDON JM, Wang K, Fulford D, Parente L, et al
    Randomized controlled trial of Understanding Social Situations versus problem-solving training in improving social function in people with psychosis.
    J Int Neuropsychol Soc. 2026 Jun 19:1-10. doi: 10.1017/S1355617726102070.
    PubMed         Abstract available


    Mol Psychiatry

  5. FRENCH H, Yao S, Bast L, Roig Adam A, et al
    Developmentally dynamic, non-convergent transcriptomic profiles in CNV models for schizophrenia risk.
    Mol Psychiatry. 2026 Jun 18. doi: 10.1038/s41380-026-03679.
    PubMed         Abstract available

  6. YU T, Lu Z, Huang B, Sun Y, et al
    Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naive first-episode schizophrenia.
    Mol Psychiatry. 2026 Jun 15. doi: 10.1038/s41380-026-03684.
    PubMed         Abstract available

  7. ZHAO G, Sun Y, Lu Z, Kang Z, et al
    Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study.
    Mol Psychiatry. 2026;31:4154-4163.
    PubMed         Abstract available

  8. FENG Y, Jia N, Huang P, Hu S, et al
    Cross-ancestry genetic architecture reveals shared biological pathways of major psychiatric disorders.
    Mol Psychiatry. 2026;31:4083-4095.
    PubMed         Abstract available

  9. GIACOMEL A, Powell TR, Duarte RRR, Nordio G, et al
    Transcriptome-informed brain cartography of polygenic risk and association with brain structure in major psychiatric disorders.
    Mol Psychiatry. 2026;31:3965-3977.
    PubMed         Abstract available

  10. GUO Z, Zhao W, Li J, Zhang H, et al
    Exploring the impact of cognitive profiles on the response to magnetic seizure therapy and electroconvulsive therapy.
    Mol Psychiatry. 2026;31:3653-3661.
    PubMed         Abstract available


    Nat Ment Health

  11. VIGNANDO M, Ffytche D, Mazibuko N, Palma G, et al
    Deviations in effective connectivity explain different hallucination subtypes in Parkinson's disease psychosis.
    Nat Ment Health. 2026;4:994-1009.
    PubMed         Abstract available

  12. BELLO D, Blyth SH, Rabin RA, Addington J, et al
    Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts.
    Nat Ment Health. 2026;4:941-950.
    PubMed         Abstract available


    Neuropsychopharmacology

  13. MAYER MR, Choo TH, Javitt DC, Kantrowitz JT, et al
    Serotonin type 3 receptor (5-HT(3)R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2026 Jun 17. doi: 10.1038/s41386-026-02467.
    PubMed         Abstract available


    Psychiatry Res

  14. ZENG Y, Wang X, Wu H, Tan X, et al
    Post-marketing safety surveillance of the novel muscarinic antipsychotic Xanomeline-Trospium for schizophrenia: A comparative disproportionality analysis against olanzapine based on FAERS data.
    Psychiatry Res. 2026;364:117270.
    PubMed         Abstract available

  15. ZHANG K, Xue H, Wang C, Li N, et al
    Adjunctive intermittent theta-burst stimulation for first-episode schizophrenia: A randomized clinical trial.
    Psychiatry Res. 2026;364:117247.
    PubMed         Abstract available


    Psychol Med

  16. REN H, Liu Y, Huang Y, Tang Y, et al
    Schizophrenia and bipolar disorder: a comparative analysis of genetic and brain network connectivity.
    Psychol Med. 2026;56:e202.
    PubMed         Abstract available

  17. TWUMASI R, Gronemann FH, Hjorthoj C, Howes O, et al
    Real-world effectiveness of antipsychotic treatment of functional outcomes over 10 years: A national cohort of patients in Denmark with schizophrenia.
    Psychol Med. 2026;56:e186.
    PubMed         Abstract available


    Schizophr Res

  18. SMAGULA SF, Kim YS, Lee E, Wallace ML, et al
    Moderators of behavioral activation versus treatment as usual effects on negative symptoms in patients with Schizophrenia Spectrum Disorder.
    Schizophr Res. 2026;295:248-252.
    PubMed         Abstract available

  19. HARRIS NM, Holter KM, Niswender CM
    Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia.
    Schizophr Res. 2026;295:236-247.
    PubMed         Abstract available

  20. OLIVARES-BERJAGA D, Rodriguez N, Martinez-Pinteno A, Rubio-Unguetti L, et al
    Increased brain VDAC1 protein levels correlate with behavioural performance in a ketamine murine model of schizophrenia and are attenuated by the mGluR2 modulator JNJ-46356479.
    Schizophr Res. 2026;295:228-235.
    PubMed         Abstract available

  21. HUANG Y, Zhang J, Ling J, Zhao L, et al
    Comparative efficacy of oral and long-acting injectable paliperidone on social functioning in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2026;295:212-225.
    PubMed         Abstract available

  22. TEAGUE V, Guilfoyle S, Pocha P, Chelvam TP, et al
    Is a higher antipsychotic dose required to treat relapse in remitted first episode psychosis? A systematic review and meta-analysis.
    Schizophr Res. 2026;295:210-211.
    PubMed        

  23. GOH KK, Wu TH, Chen CH, Chen PY, et al
    The U-shaped relationships between prolactin level and insulin resistance in patients with schizophrenia under olanzapine treatment.
    Schizophr Res. 2026;295:202-209.
    PubMed         Abstract available

  24. MASON A, Logeswaran Y, Opper F, Khan H, et al
    The effectiveness and tolerability of trauma-focused interventions for trauma symptoms in individuals who have psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2026;295:187-201.
    PubMed         Abstract available

  25. CHEN J, Dong Y, Li Y, Liu N, et al
    Energy metabolism dysregulation in schizophrenia with non-thyroidal illness syndrome: Roles of citric acid and Tyrosol-4-sulfate.
    Schizophr Res. 2026;295:179-186.
    PubMed         Abstract available

  26. KANG JT, Shields AM, Mizuno Y, De Biase M, et al
    A systematic review on the effects of clozapine on B-lymphocytes and immunoglobulins.
    Schizophr Res. 2026;294:198-214.
    PubMed         Abstract available

  27. VERDOUX H, Schulte P, Lepetit A, Montastruc F, et al
    Risk and management of cancer in clozapine users: A systematic review.
    Schizophr Res. 2026;294:99-109.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum